"Technology Transfer Challenges in MSMEs: Evaluating IP Commercialization Pathways in the Pharma Sector"

Despite their substantial contribution to pharmaceutical innovation, MSMEs have several barriers to technology transfer and IP commercialization and are likely to be greatly affected worldwide by the COVID-19 crisis. This paper looks at these challenges, assesses the current frameworks for commercialization and puts forward guidelines for how to develop effective frameworks to build on the role of MSMEs in pharmaceutical development. Utilizing a multimethod approach of topic modeling, correspondence analysis, and a trend analysis, the study shows that the process by which technology transfer and IP management takes place in pharmaceutical MSMEs is complex. The following are the major issues observed when scaling up: Strategic partnerships are crucial for commercialization, internal capacity is also a critical component and a strong focus on the market need. The study also highlights the social impacts of efficient technology transfer; of which, include improved availability and cost-effectiveness of new healthcare technologies. With regards to managerial implications, this paper establishes that there is a call for creating symbiotic relationships, staff development, and handling of market issues. Papers to be explored for future research are:- examination of the effects of the digitization and advanced technologies on technology transfer activities- the relation between technology transfer, Intellectual Property, sustainability and ethical issues in drug development. In this aspect, it is possible to identify the following challenges and opportunities that can be addressed by development stakeholders in order to ensure that innovation and development are achieved by pharmaceutical MSMEs and benefit the public health of societies, and thus the well-being of individuals and communities. DOI: https://doi.org/10.52783/pst.1104